While I have a few reservations, especially with net debt, and...

While I have a few reservations, especially with net debt, and slow down in cash flow, I believe this stock is a buy for the long-term investor. They have a unique product with hospitals somewhat dependent on their supply. The Asian opportunities are also promising, and Immulab will be a key driver once their expansion plans are realized in 2024.
The dividend, whilst modest, reflects a positive outlook, and the desire of management to meet shareholder expectations. As I bought in (via Quantum) at a modest price the return is quite adequate, and with good future prospects, I am happy to hold.